IP Library Granted Patent US 9,399,000
Granted Patent B2
US 9,399,000 · App. 13/477,396 · Granted Jul 26, 2016

Fused quartz tubing for pharmaceutical packaging

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,399,000
App. No.
13/477,396
Granted
Jul 26, 2016
Kind
B2
Abstract

A high silica glass composition comprising about 92 to about 99.9999 wt. % SiO 2 and from about 0.0001 to about 8 wt. % of at least one dopant selected from Al 2 O 3 , CeO 2 , TiO 2 , La 2 O 3 , Y 2 O 3 , Nd 2 O 3 , other rare earth oxides, and mixtures of two or more thereof. The glass composition has a working point temperature ranging from 600 to 2,000° C. These compositions exhibit stability similar to pure fused quartz, but have a moderate working temperature to enable cost effective fabrication of pharmaceutical packages. The glass is particularly useful as a packaging material for pharmaceutical applications, such as, for example pre-filled syringes, ampoules and vials.

Claims (26)

1. A pharmaceutical packaging container comprising a silica glass composition comprising about 92 to about 99.9 wt. % SiO 2 and about 0.1 to about 8 wt. % selected from Al 2 O 3 , GeO 2 , Ga 2 O 3 , CeO 2 , ZrO 2 , TiO 2 , Y 2 O 3 , a rare earth oxide, or mixtures of two or more thereof, wherein the composition does not contain an appreciable amount of alkali metals, alkaline earth metals, or borate ions.

2. The pharmaceutical packaging container of claim 1 , where the silica glass composition comprises about 96 to about 99.9 wt % SiO 2 .

3. The pharmaceutical packaging container of claim 1 , where the container is formed by thermal conversion processing of a glass article formed from the silica glass composition.

4. The pharmaceutical packaging container of claim 1 in the form of one of a vial, cartridge, syringe barrel, or ampoule.

5. The pharmaceutical packaging container of claim 1 , wherein said container is designed for the liquid or dry (lyophilized) storage of drugs.

6. The pharmaceutical packaging container of claim 1 , wherein the inner surface of the packaging container is substantially free of a coating.

7. The pharmaceutical packaging container of claim 1 , wherein the container has a total extractable metal concentration of about 8 mg/L or less when subjected to HCl digestion, the total extractable metal concentration being represented by the total concentration of Al, B, Na, Ca, K, Li, Ba, and Mg extracted upon HCl digestion.

8. The pharmaceutical packaging container of claim 1 , wherein the container exhibits the following leaching characteristics when subjected to HCl digestion: Na (<7.0 mg/L), Ca (<1.0 mg/L), B (<2.5 mg/L), Al (<1.25 mg/L), Ba (<0.003 mg/L), K (<0.03 mg/L), or Mg (<0.01 mg/L).

9. The pharmaceutical packaging container of claim 1 , wherein the container exhibits the following leaching characteristics when subjected to HCl digestion: Na (<0.1 mg/L), Ca (<0.05 mg/L), B (<0.01 mg/L), Al (<0.05 mg/L), K(<0.01 mg/L), or Mg (<0.01 mg/L).

10. The pharmaceutical packaging container of claim 1 , wherein the total concentration of metal impurities is about 0.5 wt. % or less.

11. The pharmaceutical packaging container of claim 1 , wherein the total concentration of metal impurities is about 0.015 wt. % or less.

12. The pharmaceutical packaging container of claim 1 , wherein the container produces 1000 particles/cm 2 or less when in contact with a pharmaceutical aqueous solution at pH from about 3 to 10 for 60 days.

13. The pharmaceutical packaging container of claim 1 , wherein the container produces 500 particles/cm 2 or less when in contact with a pharmaceutical aqueous solution at pH from about 3 to 10 for 60 days.

14. The pharmaceutical packaging container of claim 1 , wherein the container produces 100 particles/cm 2 or less when in contact with a pharmaceutical aqueous solution at pH from about 3 to 10 for 60 days.

15. The pharmaceutical packaging container of claim 1 , wherein the container produces 50 particles/cm 2 or less when in contact with a pharmaceutical aqueous solution at pH from about 3 to 10 for 60 days.

16. The pharmaceutical packaging container of claim 1 , wherein the container produces 10 particles/cm 2 or less when in contact with a pharmaceutical aqueous solution at pH from about 3 to 10 for 60 days.

17. The pharmaceutical packaging container of claim 1 , wherein the container has a OH concentration of 0.5% or less, a Cl concentration of 0.5% or less, or a OH concentration and Cl concentration of 0.5% or less.

18. The pharmaceutical packaging container of claim 1 , wherein the container has a OH concentration of 150 ppm or less, a Cl concentration 150 ppm or less, or a OH concentration and Cl concentration of 150 ppm or less.

19. The pharmaceutical packaging container of claim 1 , wherein the container has a OH concentration of 50 ppm or less, a Cl concentration of 50 ppm or less, or a OH concentration and Cl concentration of 50 ppm or less.

20. The pharmaceutical packaging container of claim 1 , wherein the container has a OH concentration of 10 ppm or less, a Cl concentration of 10 ppm or less, or a OH concentration and Cl concentration of 10 ppm or less.

21. The pharmaceutical packaging container of claim 1 , wherein the concentration of cations or metal ions leached from the container is lower than the concentration of cations or metals leached from a borosilicate glass and/or soda lime glass when the respective glasses are in contact with an aqueous solution.

22. The pharmaceutical packaging container of claim 1 , wherein the container is formed by a continuous draw process comprising drawing a glass composition into a rod or tube, and converting the rod or tube into the container.

23. The pharmaceutical packaging container of claim 1 , wherein the container is formed from a glass composition comprising a fine metal oxide dispersing agent.

24. The pharmaceutical packaging container of claim 21 , wherein the aqueous solution is a liquid pharmaceutical drug formulation.

25. A pharmaceutical packaging container comprising a silica glass composition comprising at least 99.9% wt. % SiO 2 and a dopant selected from Al 2 O 3 , GeO 2 , Ga 2 O 3 , CeO 2 , ZrO 2 , TiO 2 , Y 2 O 3 , a rare earth oxide, or mixtures of two or more thereof in an amount of about 0.1 to about 0.0001 wt. %.

26. The pharmaceutical packaging container of claim 25 comprising greater than about 99.95 wt. % SiO 2 .

Assignments (18)
PATENT SECURITY AGREEMENT Recorded May 23, 2025
From: MOMENTIVE PERFORMANCE MATERIALS QUARTZ, INC.
To: STANDARD CHARTERED BANK, AS COLLATERAL AGENT AND ADMINISTRATIVE AGENT
Reel/Frame 071368/0854 →
TERMINATION AND RELEASE OF SECURITY INTEREST IN PATENTS Recorded Mar 31, 2023
From: BNP PARIBAS
To: MOMENTIVE PERFORMANCE MATERIALS INC.
Reel/Frame 063259/0133 →
RELEASE OF SECURITY INTEREST Recorded Mar 30, 2023
From: KOOKMIN BANK NEW YORK
To: MOMENTIVE PERFORMANCE MATERIALS INC.
Reel/Frame 063197/0373 →
NUNC PRO TUNC ASSIGNMENT Recorded Feb 4, 2021
From: MOMENTIVE PERFORMANCE MATERIALS INC.
To: MOMENTIVE PERFORMANCE MATERIALS QUARTZ, INC.
Reel/Frame 055222/0140 →
RELEASE OF SECURITY INTEREST Recorded Nov 11, 2020
From: JPMORGAN CHASE BANK, N.A., AS COLLATERAL AGENT
To: MOMENTIVE PERFORMANCE MATERIALS INC.
Reel/Frame 054336/0023 →
FIRST LIEN TERM LOAN PATENT AGREEMENT Recorded Jun 5, 2019
From: MOMENTIVE PERFORMANCE MATERIALS INC.
To: BNP PARIBAS, AS ADMINISTRATIVE AGENT
Reel/Frame 049387/0782 →
SECOND LIEN TERM LOAN PATENT AGREEMENT Recorded Jun 5, 2019
From: MOMENTIVE PERFORMANCE MATERIALS INC.
To: KOOKMIN BANK, NEW YORK BRANCH, AS ADMINISTRATIVE AGENT
Reel/Frame 049388/0220 →
ABL PATENT AGREEMENT Recorded Jun 5, 2019
From: MOMENTIVE PERFORMANCE MATERIALS INC.; MOMENTIVE PERFORMANCE MATERIALS GMBH
To: CITIBANK, N.A., AS ADMINISTRATIVE AGENT
Reel/Frame 049388/0252 →
RELEASE OF SECURITY INTEREST Recorded May 15, 2019
From: BOKF, NA
To: MOMENTIVE PERFORMANCE MATERIALS INC.
Reel/Frame 049249/0271 →
RELEASE OF SECURITY INTEREST Recorded May 15, 2019
From: BOKF, NA
To: MOMENTIVE PERFORMANCE MATERIALS INC.
Reel/Frame 049194/0085 →
NOTICE OF CHANGE OF COLLATERAL AGENT - ASSIGNMENT OF SECURITY INTEREST IN INTELLECTUAL PROPERTY Recorded Mar 6, 2015
From: THE BANK OF NEW YORK MELLON TRUST COMPANY, N.A. AS COLLATERAL AGENT
To: BOKF, NA, AS SUCCESSOR COLLATERAL AGENT
Reel/Frame 035136/0457 →
NOTICE OF CHANGE OF COLLATERAL AGENT - ASSIGNMENT OF SECURITY INTEREST IN INTELLECTUAL PROPERTY - SECOND LIEN Recorded Mar 6, 2015
From: THE BANK OF NEW YORK MELLON TRUST COMPANY, N.A. AS COLLATERAL AGENT
To: BOKF, NA, AS SUCCESSOR COLLATERAL AGENT
Reel/Frame 035137/0263 →
TERMINATION AND RELEASE OF SECURITY INTEREST IN PATENT RIGHTS Recorded Nov 20, 2014
From: JPMORGAN CHASE BANK, N.A.
To: MOMENTIVE PERFORMANCE MATERIALS INC.
Reel/Frame 034410/0607 →
SECURITY INTEREST Recorded Oct 27, 2014
From: MOMENTIVE PERFORMANCE MATERIALS INC.
To: THE BANK OF NEW YORK MELLON TRUST COMPANY, N.A., AS COLLATERAL AGENT
Reel/Frame 034066/0570 →
SECURITY INTEREST Recorded Oct 27, 2014
From: MOMENTIVE PERFORMANCE MATERIALS INC.
To: THE BANK OF NEW YORK MELLON TRUST COMPANY, N.A., AS COLLATERAL AGENT
Reel/Frame 034066/0662 →
SECURITY INTEREST Recorded Apr 22, 2014
From: MOMENTIVE PERFORMANCE MATERIALS INC.
To: JPMORGAN CHASE BANK, N.A., AS COLLATERAL AGENT
Reel/Frame 032736/0552 →
SECURITY INTEREST Recorded Apr 22, 2014
From: MOMENTIVE PERFORMANCE MATERIALS INC.
To: JPMORGAN CHASE BANK, N.A., AS COLLATERAL AGENT
Reel/Frame 032754/0774 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 31, 2012
From: AHN, KIPYUNG; XU, GUANGJUN; PANCHULA, MARTIN; CONZONE, SAMUEL; RONG, TIANJUN; ZUYEV, KONSTANTIN; ZHOU, YAN
To: MOMENTIVE PERFORMANCE MATERIALS, INC.
Reel/Frame 029547/0790 →